{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T22:07:01Z","timestamp":1792447621218,"version":"4.5.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2006,4,20]],"date-time":"2006-04-20T00:00:00Z","timestamp":1145491200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Pharmacokinet Pharmacodyn"],"published-print":{"date-parts":[[2006,6]]},"DOI":"10.1007\/s10928-006-9012-6","type":"journal-article","created":{"date-parts":[[2006,4,19]],"date-time":"2006-04-19T14:05:01Z","timestamp":1145455501000},"page":"281-311","source":"Crossref","is-referenced-by-count":83,"title":["Disease Progression and Pharmacodynamics in Parkinson Disease \u2013 Evidence for Functional Protection with Levodopa and Other Treatments"],"prefix":"10.1007","volume":"33","author":[{"given":"Nicholas H. G.","family":"Holford","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phylinda L. S.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John G.","family":"Nutt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl","family":"Kieburtz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ira","family":"Shoulson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Parkinson Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2006,4,20]]},"reference":[{"issue":"5","key":"9012_CR1","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1001\/archneur.56.5.529","volume":"56","author":"S. Fahn","year":"1999","unstructured":"Fahn S. (1999). Parkinson disease, the effect of levodopa, and the ELLDOPA trial. Earlier vs Later L-DOPA. Arch. Neurol. 56(5):529\u2013535","journal-title":"Earlier vs Later L-DOPA. Arch. Neurol."},{"issue":"6","key":"9012_CR2","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1002\/ana.410320614","volume":"32","author":"M. Schulzer","year":"1992","unstructured":"Schulzer M., Mak E., and Calne D.B. (1992). The antiparkinson efficacy of deprenyl derives from transient improvement that is likely to be symptomatic. Ann. Neurol. 32(6):795\u2013798","journal-title":"Ann. Neurol."},{"issue":"1","key":"9012_CR3","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/ana.10609","volume":"54","author":"A.L. Whone","year":"2003","unstructured":"Whone A.L., Watts R.L., Stoessl A.J., Davis M., Reske S., Nahmias C. et\u00a0al. (2003). Slower progression of Parkinson\u2019s disease with ropinirole versus levodopa: The REAL-PET study. Ann. Neurol. 54(1):93\u2013101","journal-title":"Ann. Neurol."},{"key":"9012_CR4","doi-asserted-by":"crossref","unstructured":"Parkinson Study Group. (2002). Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. J. Am. Med. Assoc. 287(13):1653\u20131661","DOI":"10.1001\/jama.287.13.1653"},{"issue":"18","key":"9012_CR5","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1056\/NEJM199210293271801","volume":"327","author":"K.L. Davis","year":"1992","unstructured":"Davis K.L., Thal L.J., Gamzu E.R., Davis C.S., Woolson R.F., Gracon S.I. et\u00a0al. (1992). A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer\u2019s disease The Tacrine Collaborative Study Group. N. Engl. J. Med. 327(18):1253\u20131259","journal-title":"N. Engl. J. Med."},{"key":"9012_CR6","doi-asserted-by":"crossref","unstructured":"The Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson\u2019s disease. N. Engl. J. Med. 328:176\u2013183 (1993).","DOI":"10.1056\/NEJM199301213280305"},{"key":"9012_CR7","volume-title":"Handbook of Experimental Pharmacology Chapter 11","author":"N.H.G. Holford","year":"1994","unstructured":"Holford N.H.G., Ludden T. (1994). Time course of drug effect. In: Welling P.G., Balant L.P. (eds) Handbook of Experimental Pharmacology Chapter 11. Springer-Verlag, Heidelberg"},{"key":"9012_CR8","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1146\/annurev.pharmtox.41.1.625","volume":"41","author":"P.L.S. Chan","year":"2001","unstructured":"Chan P.L.S. and Holford N.H.G. (2001). Drug treatment effects on disease progression. Annu. Rev. Pharmacol. Toxicol. 41:625\u2013659","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"9012_CR9","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1146\/annurev.pharmtox.40.1.209","volume":"40","author":"N.H.G. Holford","year":"2000","unstructured":"Holford N.H.G., Kimko H.C., Monteleone J.P., and Peck C.C. (2000). Simulation of clinical trials. Annu. Rev. Pharmacol. Toxicol. 40:209\u2013234","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"9012_CR10","doi-asserted-by":"crossref","unstructured":"The Parkinson Study Group. Effect of deprenyl on the progression of disability in early Parkinson\u2019s disease. N. Engl. J. Med. 321:1364\u20131371 (1989).","DOI":"10.1056\/NEJM198911163212004"},{"key":"9012_CR11","first-page":"253","volume-title":"Principles of Clinical Pharmacology","author":"N.H.G. Holford","year":"2001","unstructured":"Holford N.H.G., Mould D.R., and Peck C.C. (2001). Disease Progress Models. In: Atkinson A. (eds). Principles of Clinical Pharmacology. Academic Press, San Diego, pp. 253\u2013262"},{"key":"9012_CR12","doi-asserted-by":"crossref","first-page":"429","DOI":"10.2165\/00003088-198106060-00002","volume":"6","author":"N.H.G. Holford","year":"1981","unstructured":"Holford N.H.G. and Sheiner L.B. (1981). Understanding the dose-effect relationship: Clinical application of pharmacokinetic-pharmacodynamic models. Clin. Pharmacokinet. 6:429\u2013453","journal-title":"Clin. Pharmacokinet."},{"key":"9012_CR13","doi-asserted-by":"crossref","first-page":"11466","DOI":"10.1073\/pnas.89.23.11466","volume":"89","author":"N.H.G. Holford","year":"1992","unstructured":"Holford N.H.G. and Peace K.E. (1992). Methodologic aspects of a population pharmacodynamic model for cognitive effects in Alzheimer patients treated with tacrine. Proc. Natl. Acad. Sci. USA 89:11466\u201311470","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"6","key":"9012_CR14","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1111\/j.1365-2125.2004.02224.x","volume":"58","author":"G. Pillai","year":"2004","unstructured":"Pillai G., Gieschke R., Goggin T., Jacqmin P., R.C. Schimmer, and Steimer J.L. (2004). A semimechanistic and mechanistic population PK-PD model for biomarker response to ibandronate, a new bisphosphonate for the treatment of osteoporosis. Br. J. Clin. Pharmacol. 58(6):618\u2013631","journal-title":"Br. J. Clin. Pharmacol."},{"key":"9012_CR15","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s10928-005-0055-x","volume":"32","author":"P.L.S. Chan","year":"2005","unstructured":"Chan P.L.S., Nutt J.G., and Holford N.H.G. (2005). Pharmacokinetic and pharmacodynamic changes during the first four years of levodopa treatment in Parkinson\u2019s disease. J. Pharmacokinet. Pharmacodyn. 32:459\u2013484","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"9012_CR16","doi-asserted-by":"crossref","unstructured":"The Parkinson Study Group. Impact of deprenyl and tocopherol treatment on Parkinson\u2019s disease in DATATOP patients requiring levodopa. Ann. Neurol. 39:37\u201345 (1996).","DOI":"10.1002\/ana.410390107"},{"key":"9012_CR17","doi-asserted-by":"crossref","unstructured":"The Parkinson Study Group. Impact of deprenyl and tocopherol treatment on Parkinson\u2019s disease in DATATOP subjects not requiring levodopa. Ann. Neurol. 39:29\u201336 (1996).","DOI":"10.1002\/ana.410390106"},{"key":"9012_CR18","doi-asserted-by":"crossref","unstructured":"The Parkinson Study Group. Mortality in DATATOP: A multicenter trial in early Parkinson\u2019s disease. Ann. Neurol. 43(3):318\u2013325 (1998).","DOI":"10.1002\/ana.410430309"},{"issue":"5","key":"9012_CR19","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1002\/ana.10191","volume":"51","author":"I. Shoulson","year":"2002","unstructured":"Shoulson I., Oakes D., Fahn S., Lang A., Langston J.W., LeWitt P. et\u00a0al. (2002). Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson\u2019s disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial. Ann. Neurol. 51(5):604\u2013612","journal-title":"Ann. Neurol."},{"key":"9012_CR20","unstructured":"Beal S.L., Boeckmann A.J., and L. B. Sheiner. NONMEM Project Group. In. NONMEM Users Guides V. Version (ed.). University of California at San Francisco, San Francisco, 1999."},{"issue":"3","key":"9012_CR21","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0009-9236(97)90160-0","volume":"61","author":"L.B. Sheiner","year":"1997","unstructured":"Sheiner L.B. (1997). Learning versus confirming in clinical drug development. Clin. Pharmacol. Ther. 61(3):275\u2013291","journal-title":"Clin. Pharmacol. Ther."},{"key":"9012_CR22","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1212\/WNL.51.2.520","volume":"51","author":"S. P\u00e5lhagen","year":"1998","unstructured":"P\u00e5lhagen S., Heinonen E.H., H\u00e4gglund J., Kaugesaar T., Kontants H., M\u00e4ki-Ikola O. et\u00a0al. (1998). Selegiline delays the onset of disability in de novo parkinsonian patients. Neurology 51:520\u2013525","journal-title":"Neurology"},{"key":"9012_CR23","first-page":"97","volume-title":"The Population Approach: Measuring and Managing Variability in Response, Concentration and Dose","author":"N.H.G. Holford","year":"1997","unstructured":"Holford N.H.G. (1997). Population models for Alzheimer\u2019s and Parkinson\u2019s disease. In: Aarons L. and Balant L.P. (eds) The Population Approach: Measuring and Managing Variability in Response, Concentration and Dose. COST B1 European Commission, Brussels, pp. 97\u2013104"},{"key":"9012_CR24","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1212\/WNL.44.7.1287","volume":"44","author":"M. Contin","year":"1994","unstructured":"Contin M., Riva R., Martinelli P., Cortelli P., Albani F., and Baruzzi A. (1994). Longitudinal monitoring of the levodopa concentration-effect relationship in Parkinson\u2019s disease. Neurology 44:1287\u20131292","journal-title":"Neurology"},{"key":"9012_CR25","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1002\/ana.410390504","volume":"39","author":"J.G. Nutt","year":"1996","unstructured":"Nutt J.G. and Holford N.H.G. (1996). The response to levodopa in Parkinson\u2019s disease: Imposing pharmacological law and order. Ann. Neurol. 39:561\u2013573","journal-title":"Ann. Neurol."},{"issue":"6","key":"9012_CR26","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1002\/ana.10189","volume":"51","author":"J.G. Nutt","year":"2002","unstructured":"Nutt J.G., Carter J.H., Lea E.S., and Sexton G.J. (2002). Evolution of the response to levodopa during the first 4\u00a0years of therapy. Ann. Neurol. 51(6):686\u2013693","journal-title":"Ann. Neurol."},{"key":"9012_CR27","doi-asserted-by":"crossref","unstructured":"Parkinson Study Group. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch. Neurol. 61(4):561\u2013566 (2004).","DOI":"10.1001\/archneur.61.4.561"},{"key":"9012_CR28","doi-asserted-by":"crossref","unstructured":"Parkinson Study Group. Levodopa and the progression of Parkinson\u2019s disease. N. Engl. J. Med. 351(24):2498\u20132508 (2004).","DOI":"10.1056\/NEJMoa033447"},{"key":"9012_CR29","doi-asserted-by":"crossref","unstructured":"Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease. J. Am. Med. Assoc. 284(15):1931\u20131938 (2000).","DOI":"10.1001\/jama.284.15.1931"},{"issue":"20","key":"9012_CR30","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1056\/NEJM200005183422004","volume":"342","author":"O. Rascol","year":"2000","unstructured":"Rascol O., Brooks D.J., Korczyn A.D., De Deyn P.P., Clarke C.E., and Lang A.E. (2000). A five-year study of the incidence of dyskinesia in patients with early Parkinson\u2019s disease who were treated with ropinirole or levodopa. 056 Study Group. N. Engl. J. Med. 342(20):1484\u20131491","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"9012_CR31","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1081\/BIP-120019265","volume":"13","author":"C.H. Mallinckrodt","year":"2003","unstructured":"Mallinckrodt C.H., Clark S.W., Carroll R.J., and Molenbergh G. (2003). Assessing response profiles from incomplete longitudinal clinical trial data under regulatory considerations. J. Biopharm. Stat. 13(2):179\u2013190","journal-title":"J. Biopharm. Stat."},{"issue":"1","key":"9012_CR32","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1023\/A:1023249510224","volume":"30","author":"C. Hu","year":"2003","unstructured":"Hu C. and Sale M.E. (2003). A joint model for nonlinear longitudinal data with informative dropout. J. Pharmacokinet. Pharmacodyn. 30(1):83\u2013103","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"9012_CR33","first-page":"231","volume":"46","author":"M.D. Muenter","year":"1971","unstructured":"Muenter M.D., and Tyce G.M. (1971). L-dopa therapy of Parkinson\u2019s disease, plasma L-dopa concentration, therapeutic response, and side effects. Mayo Clin. Proc. 46:231\u2013239","journal-title":"Mayo Clin. Proc."},{"issue":"5","key":"9012_CR34","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1136\/jnnp.69.5.590","volume":"69","author":"C.E. Clarke","year":"2000","unstructured":"Clarke C.E., and Davies P. (2000). Systematic review of acute levodopa and apomorphine challenge tests in the diagnosis of idiopathic Parkinson\u2019s disease. J. Neurol. Neurosurg. Psychiatry 69(5):590\u2013594","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"9012_CR35","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1212\/WNL.31.2.125","volume":"31","author":"C.H. Markham","year":"1981","unstructured":"Markham C.H., and Diamond S.G.(1981). Evidence to support early levodopa therapy in Parkinson disease. Neurology 31:125\u2013131","journal-title":"Neurology"},{"issue":"Suppl 3","key":"9012_CR36","doi-asserted-by":"crossref","first-page":"S184","DOI":"10.1212\/WNL.47.6_Suppl_3.184S","volume":"47","author":"S. Fahn","year":"1996","unstructured":"Fahn S. (1996). Is levodopa toxic?. Neurology 47(Suppl 3):S184\u2013S195","journal-title":"Neurology"},{"issue":"5","key":"9012_CR37","doi-asserted-by":"crossref","first-page":"339","DOI":"10.2165\/00002018-199921050-00001","volume":"21","author":"M.G. Murer","year":"1999","unstructured":"Murer M.G., Raisman-Vozari R. and Gershanik O. (1999). Levodopa in Parkinson\u2019s disease: neurotoxicity issue laid to rest? Drug Saf. 21(5):339\u2013352","journal-title":"Drug Saf."},{"issue":"9106","key":"9012_CR38","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/S0140-6736(05)70285-3","volume":"351","author":"Y. Agid","year":"1998","unstructured":"Agid Y., Chase T., and Marsden D. (1998). Adverse reactions to levodopa: drug toxicity or progression of disease?. Lancet 351(9106):851\u2013852","journal-title":"Lancet"},{"issue":"5","key":"9012_CR39","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1002\/ana.410430504","volume":"43","author":"M.G. Murer","year":"1998","unstructured":"Murer M.G., Dziewczapolski G., Menalled L.B., Garcia M.C., Agid Y., Gershanik O. et\u00a0al. (1998). Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions. Ann. Neurol. 43(5):561\u2013575","journal-title":"Ann. Neurol."},{"key":"9012_CR40","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1002\/ana.410380512","volume":"38","author":"C.W. Olanow","year":"1995","unstructured":"Olanow C.W., Hauser R.A., Gauger L., Malapira T., Koller W., Hubble J. et\u00a0al. (1995). The effect of deprenyl and levodopa on the progression of Parkinson\u2019s disease. Ann. Neurol. 38:771\u2013777","journal-title":"Ann. Neurol."},{"issue":"5","key":"9012_CR41","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1002\/mds.10226","volume":"17","author":"R.A. Hauser","year":"2002","unstructured":"Hauser R.A., and Holford N.H.G. (2002). Quantitative description of loss of clinical benefit following withdrawal of levodopa-carbidopa and bromocriptine in early Parkinson\u2019s disease. Mov. Disord. 17(5):961\u2013968","journal-title":"Mov. Disord."},{"issue":"6 Suppl 3","key":"9012_CR42","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1212\/WNL.61.6_suppl_3.S34","volume":"61","author":"A.H. Schapira","year":"2003","unstructured":"Schapira A.H. (2003). Neuroprotection in PD-A role for dopamine agonists?. Neurology 61(6 Suppl 3):S34\u201342","journal-title":"Neurology"},{"key":"9012_CR43","unstructured":"P. Chan L.S., Nutt J.G., N. Holford H.G., and Parkinson Study Group. Application of clinical trial simulation to evaluate the ELLDOPA trial design. Mov. Disord. 17(5):S111\u2013S112 (2002)."}],"container-title":["Journal of Pharmacokinetics and Pharmacodynamics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10928-006-9012-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10928-006-9012-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10928-006-9012-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T08:56:39Z","timestamp":1559465799000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10928-006-9012-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,4,20]]},"references-count":43,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2006,6]]}},"alternative-id":["9012"],"URL":"https:\/\/doi.org\/10.1007\/s10928-006-9012-6","relation":{},"ISSN":["1567-567X","1573-8744"],"issn-type":[{"value":"1567-567X","type":"print"},{"value":"1573-8744","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,4,20]]}}}